Intra-arterial chemotherapy as an adjuvant to surgery in transitional cell XXXX .

@entity632 @entity1 @entity900 @entity786 @entity150
Regional chemotherapy with intra-arterial @entity900 and @entity632 as an adjuvant to total cystectomy and urinary diversion has been evaluated in a phase I to II study. In the first 17 @entity1 chemotherapy consisted of 40 to 75 mg. per m. @entity900 intra-arterially during 30 minutes, 30 to 40 mg. per m. @entity632 intra-arterially during 60 minutes (11 @entity1 ) or 12 hours (6 @entity1 ) and 400 to 500 mg. per m. @entity786 intravenously. The remaining 8 @entity1 received 70 to 100 mg. per m. @entity900 intra-arterially during 30 minutes. Intra-arterial chemotherapy was administered through a percutaneous catheter placed in the hypogastric artery before each course. Courses were repeated at 4-week intervals. A total of 25 @entity1 received 58 courses (median 2 per @entity1 ). Clinical stages of disease in the @entity1 entering the protocol were T3aNxMo (8), T3bNx-2Mo (12) and T4a-bNxMx-1 (5). Clinical response was assessed in 24 of 25 @entity1 : 6 achieved a complete clinical response, 12 had a partial response and 7 had no response. Of 25 @entity1 16 underwent total cystectomy and urinary diversion with pathological staging as follows: ToNoMo in 3, T1NoMo in 1, T3aNoMo in 5, T3bNo-2Mo in 6 and T4NoMo in 1. Intra-arterial chemotherapy can produce a complete pathological response in @entity1 with locally advanced @entity150 and is tolerated well by most @entity1 .
